ETNB is expected to report earnings to rise 26.71% to -60 cents per share on November 07
Q3'24
Est.
$-0.61
Q2'24
Beat
by $0.08
Q1'24
Missed
by $0.08
Q4'23
Missed
by $0.01
Q3'23
Beat
by $0.08
The last earnings report on August 05 showed earnings per share of -47 cents, beating the estimate of -56 cents. With 14.40K shares outstanding, the current market capitalization sits at 783.73M.
a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases